(Q39772849)

14 September 2017

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer (English)

1 reference

14 September 2017

11

Karla Morris

1 reference

14 September 2017

3

W Kimryn Rathmell

1 reference

14 September 2017

Young E Whang

1

1 reference

14 September 2017

Andrew J Armstrong

2

1 reference

14 September 2017

Paul A Godley

4

1 reference

14 September 2017

William Y Kim

5

1 reference

14 September 2017

Raj S Pruthi

6

1 reference

14 September 2017

Eric M Wallen

7

1 reference

14 September 2017

Jeffrey M Crane

8

1 reference

14 September 2017

Dominic T Moore

9

1 reference

14 September 2017

Gayle Grigson

10

1 reference

14 September 2017

Catharine P Watkins

12

1 reference

14 September 2017

Daniel J George

13

1 reference

14 September 2017

language of work or name

1 reference

10 March 2011

1 reference

14 September 2017

1 reference

14 September 2017

31

1 reference

14 September 2017

1

1 reference

14 September 2017

82-86

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

7 January 2021

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Regulation of androgen receptor activity by tyrosine phosphorylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Phase II study of sunitinib in men with advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.018

10.1016/J.UROLONC.2010.09.018

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference